Lindbrook Capital’s Mirum Pharmaceuticals MIRM Stock Holding History

Lindbrook Capital’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$4.42K	Hold	98	–	–	﹤0.01%	1998
2024 Q4	$4.05K	Hold	98	–	–	﹤0.01%	2081
2024 Q3	$3.82K	Buy	98 +32	+48%	+$1.28K	﹤0.01%	2124
2024 Q2	$2.26K	Buy	66 +60	+1,000%	+$1.57K	﹤0.01%	2309
2024 Q1	$151	Sell	6 -188	-97%	-$5.17K	﹤0.01%	2604
2023 Q4	$5.73K	Sell	194 -16	-8%	-$484	﹤0.01%	1813
2023 Q3	$6.64K	Buy	210 +43	+26%	+$1.18K	﹤0.01%	1629
2023 Q2	$4.32K	Sell	167 -237	-59%	-$6.3K	﹤0.01%	1878
2023 Q1	$9.7K	Buy	404 +167	+70%	+$3.81K	﹤0.01%	1474
2022 Q4	$4.62K	Buy	+237	New	+$4.68K	﹤0.01%	1872
2020 Q4	–	Sell	-1,500	Closed	-$29K	–	1835
2020 Q3	$29K	Buy	1,500 +1,000	+200%	+$21.5K	0.01%	499
2020 Q2	$10K	Buy	+500	New	+$8.36K	﹤0.01%	831
2020 Q1	–	Sell	-2,000	Closed	-$49K	–	1787
2019 Q4	$49K	Buy	+2,000	New	+$21.3K	0.02%	450

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Lindbrook Capital's MIRM Position: Q1 2025 in Review

Lindbrook Capital held its Mirum Pharmaceuticals (MIRM) position steady in Q1 2025 at 98 shares worth $4.42K. The position accounts for ﹤0.01% of the portfolio, ranked #1998.

Lindbrook Capital first reported a position in MIRM in Q4 2019 and has held it in 13 quarters since. The position peaked at $49K in Q4 2019. 214 funds tracked by Wall St. Rank hold MIRM as of Q1 2025.

Lindbrook Capital held 98 shares of Mirum Pharmaceuticals worth $4.42K as of Q1 2025.
Lindbrook Capital left its Mirum Pharmaceuticals share count unchanged in Q1 2025.
Mirum Pharmaceuticals made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1998 holding.
Lindbrook Capital first reported a position in Mirum Pharmaceuticals in Q4 2019 and has held it in 13 quarters since.
Lindbrook Capital's Mirum Pharmaceuticals position peaked at $49K in Q4 2019.
214 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.